5-MeO-DMT Compound Timeline

1560

Colombia natives take yopo, along the Rio Guaviare in Colombia reports of natives taking yopo along with tobacco.

Snuff; Yopo; tobacco; cohoba; psychoactive; indigenous peoples; drug combination

1936

5-MeO-DMT was first synthesized by Hoshino and Shimodaira at the Technical University of Munich, Germany and Tokyo University, Japan.

Synthesis

1962

5-MeO-DMT was extracted from the plant source Piptadenia peregrina, also known as the Cohoba tree in the Carribean and South America by Legler and Tschesche at the Chemical Institute Bonn, Germany.

Chemical extraction; plant source

1964

5-MeO-DMT toxicity first reported as a lethal syndrome called “staggers” in sheep after grazing on Phalaris tuberose.

Toxicity; adverse effect; animal research

1965

The first published analysis of the venom of the Bufo alvarius toad, the report showed presence of animal source 5-MeO-DMT in quantities as much as 15% of the dry weight of the toad parotoid and tibial glands. A more comprehensive study came out in the Journal of Pharmacology in 1967 by Erspamer et al. from Italy and Argentina.

Toad venom; Bufo alvarius toad; animal research; chemical extraction

1968

Journal article published "Structure-Activity Relationships Among 5-Methoxy-N, N-Dimethyltryptamine, 4-Hydroxy-N,N-Dimethyltryptamine (Psilocin) and other substituted Tryptamines."

Structure; tryptamines; psilocin

1970

A study done by Shulgin report 5-10 mg of 5-MeO-DMT was active by parenteral injection.

Dose; human trial; delivery method

1971

Church of the Tree of Life sacrament.

Church; Ritual; plant

1975

A report showed the presence of 5-MeO-DMT in human pineal extract using crystallization chromatography technology.

Detection; endogenous source; pineal gland; crystallization chromatography

1976

Christian established that DMT is a neurotransmitter.

DMT; endogenous source; neurotransmitter

1979

Mouse head twitch test.

Animal research; behavioral test; serotonin

1982

A report publishes in the Journal of Natural Products showed that the poison of dart points, prepared by the Yanoarna tribes of Upper Orinoco of the Roraima territory of Brazil contained plant sourced 5-MeO-DMT. This was used during hunting to cause behavioral disturbances in pray. The original date of use is unknown, darts were purchased through the Ministeriodo Interior, Fundacao National do Indio (FUNAI) Brazil for the investigative report.

Yonarna tribe; behavioral disturbance; hunting

1983

A report by Shulgin in DeSmet showed experiments with nine human subjects, finding that smoking 6-10 mg of the free base of 5-MeO-DMT produced an entheogenic effect starting in less than 60 seconds, reaching a peak in two to three minutes and lasting about twenty minutes.

human trail; Shulgin; dose; delivery method; entheogenic effect; time course

1984

Publication of underground pamphlet titled “Bufo Alvarius, the Psychedelic Toad of the Sonoran Desert” by Albert Most (Ken Nelson). The pamphlet gave detailed instructions for collecting, drying and smoking the venom.

Bufo Alvarius toad; toad venom; animal research; instruction; Albert Most; Ken Nelson; delivery method; extraction method

1985

Journal publication "Blockade and Reversal of 5-Methoxy-N,N-Dimethyltryptamine-Induced Analgesia Following Noradrenaline Depletion." Brain Research, 333, 55-61.

1988

“Treatment of mammals suffering from damage to the central nervous system” application is granted.

1992

Journal publication “Identity of a New World Psychoactive Toad.” Ancient Mesoamerica 3 (1992).

Bufo alvarius toad; toad venom

1993

Pharmacotheon: Entheogenic Drugs, Their Plant Sources and History - Jonathan Ott

1996

“Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma” is filed. Describes a method for controlling intraocular pressure, which comprises, administering topically to the eye of a person suffering from glaucoma or ocular hypertension a composition comprising a therapeutically effective amount of a 5-HT1A receptor agonist that inhibits adenylyl cyclase where the receptor agonist is selected from the group consisting of R(+) 8-hydroxy dipropylamino tetraline and 5-methoxy-N,N- dimethyltryptamine.

Serotonin; treatment; glaucoma

1997

Shulgin publishes TIHKAL. TiHKAL: The Continuation is the sequel to PiHKAL: A Chemical Love Story but can stand alone to any reader.

Shulgin; TIHKAL

2000

Jonathan Ott presents at SF Ayahuasca conference on oral dosages

Conference; dose; ayahuasca

2001

“Pharmaceutical use of compounds which bind to a mammalian ‘trace amine’ receptor” is filled. Though far broader than this, this patent involves the use of compounds, including 5-MeO-DMT, to address the pathological conditions of shock, hypertension, cardiac arrhythmia, asthma, migraine headache, psychosis, anaphylactic reactions and iatrogenic conditions (relates specifically to claims 5, 8, 10).

Treatment; shock; hypertension; ardiac arrhythmia; asthma; migraine headache; psychosis; anaphylactic reactions; iatrogenic conditions

2001

Oral, intranasal, and sublingual administration of 5-MeO-DMT in humans Ott at 30mg.

Dose; human trial; delivery method

2001

Entheobotanica - Jonathan Ott - info from shamanic snuffs or entheogenic errhines - “5-MeO-DMT--Intranasal Psychonautics [MN] I conducted in all six bioassays (MN-I-MN-VI) by way of modeling the Virola snuffs.”

Snuff; delivery method; entheogenic effect; dose

2006

"Methods and combination therapies for treating alzheimer's disease" Abandoned application. 10/27/2006

Treatment; Alzheimer's disease; therapy

2007

Mechanism. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain.

Serotonin; CNS; animal research; mechanism; psychoactive drug

2009

Tryptamine Palace: 5-MeO-DMT & the Sonoran Desert Toad, by James Oroc. A journey from Burning Man to the Akashic Field that suggest how 5-MeO-DMT triggers the human capacity for higher knowledge through direct contact with the zero-point field. Examines Bufo alvarius toad venom, which contains the potent natural psychedelic 5-MeO-DMT, and explores its entheogenic use. Proposes a new connection between the findings of modern physicas and the knowledge held by shamans and religious sages for millennia.

Bufo alvarius toad; toad venom; tryptamine; history

2010

Psychedelic 5-Methoxy-N,N-dimethyltryptamine: Metabolism, Pharmacokinetics, Drug Interactions, and Pharmacological Actions.

Delivery method; dose; human trial; animal research; review; mechanism

2013

June 2013 Ortiz begins administering 5meo following Ibogaine treatment for addiction at Crossroads Treatment Center.

Treatment; addiction; drug combination; Ibogaine

2015

Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities. Thus, as a target for future pharmacological investigations, DMT emerges as a potent and promising candidate in novel therapies of peripheral and CNS autoimmune diseases (such as multiple sclerosis or amyotrophic lateral sclerosis) and cancer.

Treatment; Therapy; DMT; CNS; autoimmune diseases; MS; Multiple sclerosis; ALS; amyotrophic lateral sclerosis; cancer

2017

“Nicotine free herbal composition for smoking de-addiction and treatment of side-effects and/or ailments from smoking” is filed. This provides nicotine free anti-smoking compositions comprising synergistic combination of herbal ingredients, including those containing 5-MeO-DMT.

Nicotine; addition; treatment; drug combination

2018

“Methods of treating food allergy conditions” is filled. Describes methods that include administering to a subject in need thereof a psychedelic agent (including 5-MeO-DMT) in a manner effective to treat the subject for a food allergy condition. Effective administration of a psychedelic agent may include administering the psychedelic agent in an amount effective to treat the subject for the food allergy condition. In some instances, the subject is known to have a food allergy condition.

Case report; traumatic brain injury; treatment

2018

The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and. reasons for consumption. "Furthermore, of those who reported being diagnosed with psychiatric disorders, the majority reported improvements in symptoms following 5-MeO-DMT use, including improvements related to post-traumatic stress disorder (79%), depression (77%), anxiety (69%), and alcoholism (66%) or drug use disorder (60%)."

Treatment; epidemiology; therapy; depression; PTSD; anxiety; alcoholism; addiction; drug use disorder

2018

Journal article published “Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study”

Human trial; mystical experience

2019

5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety.

Set and setting; naturalistic setting; delivery method; treatment; depression; anxiety; group setting

2020

Sherwood (Usona) reported synthesis of 5-MeO-DMT succinate for clinical use. Sherwood (2020) Synthesis and characterization of 5-MeO-DMT succinate for clinical use ACS Omega 5: 32067−75.

Sherwood; synthesis; clinical use

2020

“Opioid abuse-deterrent controlled release formulations” is granted.

Opioid abuse deterrent; addiction; treatment; dose; delivery method

2021

“Methods of treating food allergy conditions” is granted.

Treatment; allergy; dose

2021

Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study. Psychedelic drug (including 5-MeO-DMT) users, especially regular ones, reported less psychological distress, less peritraumatic stress, and more social support.

Human trial; COVID-19; psychometric measures; transcultural study; treatment; decreased stress; increased social support